Experienced in Urea Cycle Disorders (UCD)

Eyal Shteyer

Shmuel Bait St 12, 
Jerusalem, JM, IL 
Experienced in Urea Cycle Disorders (UCD)
Shmuel Bait St 12, 
Jerusalem, JM, IL 
OverviewLocationsClinical Research

Overview

Eyal Shteyer practices in Jerusalem, Israel. Mr. Shteyer is rated as an Experienced expert by MediFind in the treatment of Urea Cycle Disorders (UCD). His top areas of expertise are Sclerosing Cholangitis, Progressive Familial Intrahepatic Cholestasis Type 1, Cholangitis, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Urea Cycle Disorders (UCD).

Gender
Male

Locations

Shmuel Bait St 12, Jerusalem, JM, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)
A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: Odevixibat
Study Phase: Phase 3
A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, With an Optional Open-Label Extension to Assess the Safety, Tolerability, and Pharmacokinetics of Obeticholic Acid in Pediatric Subjects With Biliary Atresia
A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, With an Optional Open-Label Extension to Assess the Safety, Tolerability, and Pharmacokinetics of Obeticholic Acid in Pediatric Subjects With Biliary Atresia
Enrollment Status: Terminated
Publish Date: March 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

66 Total Publications

Human DNA levels in feces reflect gut inflammation and associate with presence of gut species in IBD patients across the age spectrum.
Human DNA levels in feces reflect gut inflammation and associate with presence of gut species in IBD patients across the age spectrum.
Journal: Research square
Published: July 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Shteyer's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile